<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3054">
  <stage>Registered</stage>
  <submitdate>21/01/2011</submitdate>
  <approvaldate>21/01/2011</approvaldate>
  <nctid>NCT01281774</nctid>
  <trial_identification>
    <studytitle>A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers</studytitle>
    <scientifictitle>An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-HDL-10-68</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - CSL112
Other interventions - Placebo

Experimental: CSL112 - Multiple ascending intravenous doses of CSL112

Placebo Comparator: Placebo - Multiple intravenous infusions of placebo


Other interventions: CSL112
reconstituted high density lipoprotein

Other interventions: Placebo
Normal saline (0.9%)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The frequency of drug-related adverse events</outcome>
      <timepoint>Up to 6 days after each infusion</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The frequency of redness and swelling at the infusion site</outcome>
      <timepoint>up to 24 hours after each infusion</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinically important elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)</outcome>
      <timepoint>up to 6 days after each infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile of apoA-I after multiple intravenous infusions</outcome>
      <timepoint>up to 7 days after each infusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy males and females aged 18 years to less than 55 years

          -  Body weight 50kg or greater

          -  Body mass index (BMI) between 18 and 42.0 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Evidence of a clinically significant medical condition, disorder or disease

          -  Evidence of hepatobiliary disease

          -  Any clinically relevant abnormal laboratory test result

          -  Evidence or history of alcohol or substance abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Q-Pharm - Brisbane</hospital>
    <postcode>4006 - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CSL Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      CSL112 in healthy volunteers after multiple infusions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01281774</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Senior Director, Cardiovascular</name>
      <address>CSL Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>